Skip to main content
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
letter
. 2004 Nov;63(11):1531–1532.

Long term treatment of psoriatic arthritis with infliximab

B Yazdani-Biuki, K Wohlfahrt, A Mulabecirovic, T Mueller, J Hermann, W Graninger, H Brezinschek, R Brezinschek, D Gladman
PMCID: PMC1754799  PMID: 15479917

Full Text

The Full Text of this article is available as a PDF (59.4 KB).

Figure 1.

Figure 1

 Changes in (A) TJC, (B) SJC, and (C) C reactive protein levels (normal value <9 mg/l) of each patient during the respective treatment period. Infliximab treatment was stopped because of insufficient response (1) or allergic reaction (2). Disease exacerbation occurred when infliximab was stopped owing to herpes labialis infection (3). Shortening of the infliximab application interval to 4 weeks (4).


Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES